摘要
目的分析miRNA-129与miRNA-21在前列腺癌患者血清中的表达水平及临床意义。方法采用实时荧光定量PCR检测40例前列腺癌、28例良性肿瘤患者以及12例健康对照者血清miRNA-129与miRNA-21的相对表达水平,分析其表达与临床病理因素的相关性。结果前列腺癌患者组的miRNA-129的相对表达量低于良性肿瘤患者和对照组,且良性肿瘤患者低于对照组,差异均有统计学意义(P<0.01)。前列腺癌患者组的miRNA-21的相对表达量高于良性肿瘤患者和对照组,且良性肿瘤患者高于对照组,差异均有统计学意义(P<0.05)。miRNA-129在肿瘤分化程度越低、病理分期越高的患者中表达水平越低,而miRNA-21则相反。结论 miRNA-129和miRNA-21可作为非侵入性诊断前列腺癌并且判断其病情的分子标志物。
Objective To analyze the serum expression levels and clinical significance of miRNA-129 and miRNA-21 in prostate cancer patients. Methods 40 prostate cancer patients,28 patients with benign prostatic hyperplasia and 12 healthy volunteers were chosen to analyze the expression levels of serum miRNA-129 and miRNA-21,so as to analyze the correlation with the clinical pathological factors. Results The expression of miRNA-129 of patients with benign prostatic hyperplasia was also lower than that of the healthy population,with the differences statistically significant( P 〈 0. 01). The expression of miRNA-21 was higher for prostate cancer patients as compared to the other two groups,while the level of miRNA-21 for patients with benign prostatic hyperplasia was also significantly higher than that in the healthy counterparts,with the differences statistically significant( P 〈 0. 05). The lower the degree of tumor differentiation was,the lower the level of miRNA-129 expression in patients with higher pathological stage was,while miRNA-21 was the opposite. Conclusion miRNA-129 and miRNA-21 can be used as a molecular marker for non-invasive diagnosis of prostate cancer and judging the severity of this disease.
出处
《中国卫生检验杂志》
CAS
2016年第19期2807-2809,共3页
Chinese Journal of Health Laboratory Technology
基金
台州市医学会科学研究基金(TZSYXH15-31)